このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

A Multicenter Phase 1 Study of Orca-Q in Primary Progressive Multiple Sclerosis

2026年11月9日 更新者:Orca Biosystems, Inc.

動員された末梢血に由来する設計されたドナー移植片であるORCA-Qを使用した原発性進行性多発性硬化症の同種造血細胞移植の多施設第1相研究

A study of allogeneic hematopoietic cell transplantation (alloHCT) with Orca-Q for the treatment of primary progressive multiple sclerosis (PPMS).

調査の概要

詳細な説明

This study will evaluate alloHCT with Orca-Q, an allogeneic hematopoietic graft isolated from a donor's hematopoietic cells for the treatment of PPMS.

研究の種類

介入

入学 (推定)

10

段階

  • フェーズ 1

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

  • 名前:James S. McClellan, MD, PhD
  • 電話番号:650-246-9601
  • メール:info@orcabio.com

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~65年 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria (Recipient):

  1. Participants aged ≥18 and ≤65 years with PPMS

    a. A diagnosis of PPMS by 2024 McDonald criteria and 2013 clinical course revision

  2. Cerebrospinal fluid (CSF) with elevated IgG index or 2 or more oligoclonal bands

  3. EDSS between 2.0 and 5.5 inclusive

  4. Based on review of the clinical records, there must be a deterioration in the EDSS of at least 1 or more points over the previous 4 years (or less)

  5. Eligibility criteria confirmed by the Eligibility Review Group

  6. Recipients who have been treated with ocrelizumab, rituximab, ofatumumab, ublituximab, or alemtuzumab must undergo a washout period as specified in the protocol prior to their planned day 0

  7. Recipients must be willing to undergo mobilized autologous peripheral blood stem cell collection to create a cryopreserved rescue product prior to alloHCT

  8. Willing to undergo MAC preparative regimen

  9. Matched to either a related or unrelated donor as follows:

    1. Matched related donor who is a 10/10 match for HLA-A, -B, -C, -DRB1 and -DQB1, all typed using DNA-based high-resolution methods
    2. Matched unrelated donor who is a 10/10 match at HLA-A, -B, -C, -DRB1 and -DQB1, all typed using DNA-based high-resolution methods
  10. Negative serum or urine β-HCG test in persons of childbearing potential

Exclusion Criteria:

  1. History of Progressive Multifocal Leukoencephalopathy

  2. Organ dysfunction or disease that would jeopardize survival after hematopoietic cell transplantation, including but not limited to the following:

    1. Renal insufficiency as defined by an estimated GFR <60 mL/minute
    2. Cardiac dysfunction as defined by symptomatic coronary artery disease, congestive heart failure, valvular heart disease, cardiomyopathy, uncontrolled arrhythmia(s), or left ventricular ejection fraction <50%. Participants with a history of these conditions may enroll if they are demonstrated to have optimal cardiac function (as defined by echocardiography or multi-gated acquisition scan)
    3. Pulmonary dysfunction that poses a risk of mortality after transplant, defined as pre-transplant pulmonary function testing demonstrating a FEV1 <70% expected and/or a DLCOadj <70% expected
    4. Necroinflammatory or fibrotic liver disease with evidence of liver dysfunction, including but not limited to jaundice, hepatic encephalopathy, or portal hypertension
    5. Marrow dysfunction that poses a risk of peri-transplant mortality, defined as an absolute neutrophil count (<1000/mm3) below the lower limit of normal, or a platelet count below 50,000/mm3
    6. Poorly controlled hypertension despite appropriate therapy, defined as a diastolic blood pressure greater than 90 mm Hg while on therapy
    7. Poorly controlled diabetes mellitus, defined as HgbA1c ≥ 6.5% despite therapy or recurrent hypoglycemia while on therapy
    8. Extreme protein-calorie malnutrition defined by Body Mass Index <18 and unintentional weight loss (3 kg in the last month or 6 kg in the last 6 months.)
  3. History of smoking either tobacco or other herbal products in the last 3 months

  4. Planned pharmaceutical in vivo or ex vivo T cell depletion (TCD), (eg, cladribine, or peritransplant antithymocyte globulin [ATG]). For participants who have previously been exposed to a TCD agent, a 5-half-life washout of the agent must occur prior to planned day 0 (day 0 is defined as the day of Orca-Q infusion). The washout period for alemtuzumab is specified in the protocol

  5. HIV seropositive

  6. HBV serology results indicating chronic HBV infection per https://www.cdc.gov/hepatitis/hbv/interpretationOfHepBSerologicResults.htm, unless HBV PCR negative. HBV seropositive participants should be on antiviral therapy after transplant

  7. HCV seropositive, unless PCR negative and having undergone 'curative' antiviral therapy

  8. Participant has active uncontrolled infection

  9. Participant has demonstrated lack of compliance with prior medical care

  10. Participants with known active malignancy. It is recommended that patients are current on cancer screening tests for their age and family history as per the NCCN [The National Comprehensive Cancer Network®] Guidelines. Screening should be performed, if indicated, per NCCN guidelines prior to study treatment.

  11. Participants whose life expectancy is severely limited by illness other than multiple sclerosis

  12. Females who are pregnant or breast feeding

  13. Medical or psychiatric conditions that compromise ability to give informed consent or to comply with treatment protocol

  14. Inability to undergo an MRI scan

  15. Currently receiving treatment with investigational agents

  16. Positive for JC virus DNA in the CSF or blood during screening

  17. Known allergy or hypersensitivity to or intolerance of tacrolimus

  18. Documented allergy or hypersensitivity to iron dextran or bovine, murine, algal, or Streptomyces avidinii proteins

  19. Recipient-positive antidonor HLA antibodies against a mismatched allele in the selected donor determined by either of the following:

    1. Positive crossmatch test of any titer (by complement-dependent cytotoxicity or flow cytometric testing) to any of the following HLA loci (if mismatched): HLA-A, HLA-B, HLA-C, HLA-DRB1, HLA-DQB1, HLA-DQA1, HLA-DPB1, or HLA-DPA1
    2. Presence of antidonor HLA antibody to any of the following HLA loci (if mismatched): HLA-A, HLA-B, HLA-C, HLA-DRB1, HLA-DQA1, or HLA-DPB1, with mean fluorescence intensity ≥1000 by solid phase immunoassay
  20. People of childbearing potential (POCBP) or men who have sexual contact with POCBP who are unwilling to use effective forms of birth control or abstinence for 1 year after transplantation

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:なし
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Orca-Q Graft with myeloablative conditioning regimen

Donor Orca-Q stem cell graft

Allogeneic (donor) stem cell graft

Myeloablative regimen of busulfan, fludarabine, and thiotepa.

他の名前:
  • ブスルファン
  • フルダラビン
  • Thiotepa

Graft-versus-host disease (GVHD) prevention

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Severe acute graft-versus-host-disease-free survival
時間枠:Up to 6 months after infusion

Number of participants who are alive without a history of grade ≥3 (severe) acute graft-versus-host disease (aGVHD), graded per Mount Sinai Acute GVHD International Consortium (MAGIC) criteria (range: grades 0-4 with higher number being worse)

Up to 6 months after infusion

二次結果の測定

結果測定
メジャーの説明
時間枠
Event-Free Survival (EFS)
時間枠:Up to 24 months and at year 5 after Orca-Q infusion

Participant is alive and free of PPMS progression. An event is defined as sustained loss of neurological function (Expanded Disability Status Scale [EDSS, range of 0-10 with higher numbers being worse] increase >1 point sustained for 3 months), relapse, one or more new or enlarging MRI lesions, or death

Up to 24 months and at year 5 after Orca-Q infusion
Loss of Neurological Function or Relapse
時間枠:Every 3 months through Month 12 and every 6 months from Months 13-24 after transplant

Assessment of sustained neurological worsening as measured by EDSS (>1-point increase) or occurrence of PPMS relapse. EDSS spans the range of 0-10 with higher numbers being worse

Every 3 months through Month 12 and every 6 months from Months 13-24 after transplant
Overall Survival (OS)
時間枠:From transplant through 5 years after transplant

Time in years from transplant to death from any cause

From transplant through 5 years after transplant
Treatment-Related Mortality (TRM)
時間枠:From start of alloHCT through 5 years after transplant

Death definitely or probably resulting from study treatment and not attributable to other causes, as determined by review of clinical and autopsy data

From start of alloHCT through 5 years after transplant
Incidence of Disease-Modifying Therapy Use for PPMS After Orca-Q
時間枠:From Orca-Q infusion through 5 years after transplant

Number of participants with initiation or re-initiation of disease-modifying therapy for PPMS following Orca-Q infusion. Use of therapies for GVHD or other transplant-related conditions is excluded

From Orca-Q infusion through 5 years after transplant
Incidence of aGVHD
時間枠:From transplant through 5 years after transplant

Number of participants with aGVHD

From transplant through 5 years after transplant
Severity of aGVHD
時間枠:From transplant through 5 years after transplant

Severity is graded per MAGIC criteria

From transplant through 5 years after transplant
Incidence chronic graft-versus-host disease (cGVHD)
時間枠:From transplant through 5 years after transplant

Number of participants with cGVHD

From transplant through 5 years after transplant
Severity of cGVHD
時間枠:From transplant through 5 years after transplant

cGVHD severity will be categorized using NIH global severity scores of mild, moderate, and severe cGVHD

From transplant through 5 years after transplant
Incidence of Primary Graft Failure
時間枠:Through day +28

Number of participants alive without recovery of neutrophils [ie, without achieving an abosolute neutrophil count (ANC) ≥500/mm3 for 3 consecutive days] at day +28 without another identifiable cause

Through day +28
Incidence of Secondary Graft Failure
時間枠:Through day +100

Number of participants with neutrophil engraftment followed by subsequent decline in ANC <500/mm3, unresponsive to growth factor therapy, by day +100 without another identifiable cause

Through day +100
Time to Neutrophil Engraftment
時間枠:From transplant through Day +365

Neutrophil engraftment is defined as an absolute neutrophil count (ANC) of 500 or more neutrophils per μL blood, sustained for 3 days in a row. The day of neutrophil engraftment is defined as the first day of ANC ≥ 500/μL. Time to neutrophil engraftment is measured in days.

From transplant through Day +365
Development of Infectious Complications
時間枠:From transplant through Day +730 (2 years), with long-term follow-up through 5 years

Incidence of definite and probable viral, fungal, and bacterial infections occurring after transplantation

From transplant through Day +730 (2 years), with long-term follow-up through 5 years
Regimen-Related Toxicity
時間枠:From start of conditioning through 1 year after transplant

Number of participants with regimen-related toxicities (adverse events attributed to the conditioning regimen, Orca-Q, or GVHD prophylaxis), graded per the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 6.0 (range: Grade 1-5, with higher grades being worse).

From start of conditioning through 1 year after transplant

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2027年3月1日

一次修了 (推定)

2028年6月1日

研究の完了 (推定)

2032年12月1日

試験登録日

最初に提出

2025年2月3日

QC基準を満たした最初の提出物

2025年3月26日

最初の投稿 (実際)

2025年3月28日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月13日

QC基準を満たした最後の更新が送信されました

2026年11月9日

最終確認日

2026年11月1日

詳しくは

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する